BRPI0418306A - inibidores da transcriptase reversa não nucleotìdicos - Google Patents

inibidores da transcriptase reversa não nucleotìdicos

Info

Publication number
BRPI0418306A
BRPI0418306A BRPI0418306-1A BRPI0418306A BRPI0418306A BR PI0418306 A BRPI0418306 A BR PI0418306A BR PI0418306 A BRPI0418306 A BR PI0418306A BR PI0418306 A BRPI0418306 A BR PI0418306A
Authority
BR
Brazil
Prior art keywords
alkyl
orx
transcriptase inhibitors
reverse transcriptase
nrxrx
Prior art date
Application number
BRPI0418306-1A
Other languages
English (en)
Inventor
Christian Sund
Nathalie Roue
Lindstr M Stefan
Dmitry Antonov
Christer Sahlberg
Katarina Jansson
Original Assignee
Medivir Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0400021A external-priority patent/SE0400021D0/xx
Priority claimed from SE0400585A external-priority patent/SE0400585D0/xx
Application filed by Medivir Ab filed Critical Medivir Ab
Publication of BRPI0418306A publication Critical patent/BRPI0418306A/pt
Publication of BRPI0418306B1 publication Critical patent/BRPI0418306B1/pt
Publication of BRPI0418306B8 publication Critical patent/BRPI0418306B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

INIBIDORES DE TRANSCRIPTASE RESERVA NãO NUCLEOTìDICOS Compostos de fórmula Z: onde; A é CH ou N; R~ 1~ é um sustituinte para um átomo de carbono no anel contendo A selecionado de -S(=O) ~ p~Ra, onde Ra é -alquilC~ 1~-C~ 4~- ORx, -NRxRx, -NHNRxRx, -NHNHC (=O) ORx, -NRxOH; -C(=O) -Rb, onde Rb é -alquilC~ 1~-C~ 3~-C(=O) ORx -NRxRc, onde Rc é H, alquilC~ 1~-C~ 4~, -NRxRx; -C(=O) Rd, -CN, S (=O) ~ p~Rx onde Rd é Rd é alquilC~ 1~-C~ 4~, -ORx, -NRxRx -alquilC~ 1~-C~ 3~-O-alquilC~ 1~-C~ 3~ C(=O) ORx, -alquilC~ 1~-C~ 3~-COORx; éteres ou ésteres -alquilC~ 1~-C~ 3~-OH ou alquilC~ 1~-C~ 4~ dos mesmos - (O-alquilC1-C3) ~ q~-O-Rx um anel aromático de 5 ou 6 membros tendo de 1-3 heteroátomos p é 1 ou 2; Rx é independentemente selecionado de H, alquilC~ 1~-C~ 4~ ou acetil; ou par de Rx pode junto com o átomo de N adjacente formar um anel; L é -O-, -S(=O)~ r~- ou -CH~ 2~-, onde r é 0, 1 ou 2; R3-R7 são substituintes como definido na especificiação; X é - (CR~ 8~R~ 8~ ) n-D- (CR~ 8~R~ 8~ ) m-; D é uma ligação, -NR~ 9~-, -O-, -S-, -S(=O) - ou -S(=O)~ 2~-; e sais farmaceuticamente aceitáveis e pró- drogas dos mesmos, tendo utilidade como anti-virais para HIV.
BRPI0418306A 2004-01-08 2004-12-30 composto n-[(1s,1ar,7br)-4,7-difluoro-1,1a,2,7b-tetraidrociclopropa[c]cromen-1-il]-n’-[5-(4-(sulfonamido)fenoxi)-2-piridinil]ureia, composição farmacêutica e uso do dito composto para profilaxia ou tratamento de infecções por hiv-1 BRPI0418306B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0400021A SE0400021D0 (sv) 2004-01-08 2004-01-08 Non-nucleoside reverse transcriptase inhibitors
SE0400585A SE0400585D0 (sv) 2004-03-09 2004-03-09 NNRTI Antivirals
PCT/SE2004/002034 WO2005066131A1 (en) 2004-01-08 2004-12-30 Non-nucleotide reverse transcriptase inhibitors

Publications (3)

Publication Number Publication Date
BRPI0418306A true BRPI0418306A (pt) 2007-05-02
BRPI0418306B1 BRPI0418306B1 (pt) 2018-09-18
BRPI0418306B8 BRPI0418306B8 (pt) 2021-05-25

Family

ID=34752289

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0418306A BRPI0418306B8 (pt) 2004-01-08 2004-12-30 composto n-[(1s,1ar,7br)-4,7-difluoro-1,1a,2,7b-tetraidrociclopropa[c]cromen-1-il]-n’-[5-(4-(sulfonamido)fenoxi)-2-piridinil]ureia, composição farmacêutica e uso do dito composto para profilaxia ou tratamento de infecções por hiv-1

Country Status (15)

Country Link
US (1) US7915295B2 (pt)
EP (1) EP1701942B1 (pt)
JP (1) JP4762917B2 (pt)
AT (1) ATE451357T1 (pt)
AU (1) AU2004312284B2 (pt)
BR (1) BRPI0418306B8 (pt)
CA (1) CA2550187C (pt)
DE (1) DE602004024584D1 (pt)
DK (1) DK1701942T3 (pt)
EA (1) EA009700B1 (pt)
ES (1) ES2337794T3 (pt)
IL (1) IL176740A (pt)
NZ (1) NZ548367A (pt)
SG (1) SG149070A1 (pt)
WO (1) WO2005066131A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003260492B2 (en) * 2002-09-05 2007-03-01 Medivir Ab Non-nucleoside reverse transcriptase inhibitors
US7388008B2 (en) 2004-08-02 2008-06-17 Ambrilia Biopharma Inc. Lysine based compounds
ES2539527T3 (es) * 2005-04-27 2015-07-01 Taimed Biologics, Inc. Método para mejorar la farmacocinética de los inhibidores de las proteasas y de los precursores de los inhibidores de las proteasas
CA2632095A1 (en) 2005-11-30 2007-06-07 Ambrilia Biopharma Inc. Lysine-based prodrugs of aspartyl protease inhibitors and processes for their preparation
GB0608876D0 (en) * 2006-05-05 2006-06-14 Medivir Ab Combination therapy
WO2007136572A2 (en) * 2006-05-15 2007-11-29 Merck & Co., Inc. Antidiabetic bicyclic compounds
EP2064177B1 (en) 2006-09-21 2017-04-05 TaiMed Biologics, Inc. Protease inhibitors
JP6636031B2 (ja) * 2015-01-30 2020-01-29 ジェネンテック， インコーポレイテッド 治療用化合物およびその使用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR016169A1 (es) * 1998-01-16 2001-06-20 Medivir Ab Compuesto, composicion farmaceutica que lo comprende y uso del mismo en la fabricacion de un medicamento para el tratamiento o profilaxis del vih.
WO1999051613A1 (en) * 1998-04-03 1999-10-14 Medivir Ab Prodrugs of phosphorous-containing pharmaceuticals
SE0100733D0 (sv) * 2001-03-05 2001-03-05 Medivir Ab Non-nucleoside reverse transcriptase inhibitors
SE0102867D0 (sv) * 2001-08-28 2001-08-28 Medivir Ab Non-nucleoside reverse transcriptase inhibitors
AU2003260492B2 (en) * 2002-09-05 2007-03-01 Medivir Ab Non-nucleoside reverse transcriptase inhibitors

Also Published As

Publication number Publication date
SG149070A1 (en) 2009-01-29
AU2004312284A1 (en) 2005-07-21
US20080070951A1 (en) 2008-03-20
IL176740A0 (en) 2006-10-31
BRPI0418306B1 (pt) 2018-09-18
EA009700B1 (ru) 2008-02-28
CA2550187A1 (en) 2005-07-21
BRPI0418306B8 (pt) 2021-05-25
AU2004312284A2 (en) 2005-07-21
AU2004312284B2 (en) 2010-08-05
EP1701942B1 (en) 2009-12-09
JP4762917B2 (ja) 2011-08-31
EP1701942A1 (en) 2006-09-20
ES2337794T3 (es) 2010-04-29
DK1701942T3 (da) 2010-04-06
DE602004024584D1 (de) 2010-01-21
CA2550187C (en) 2012-08-07
EA200601289A1 (ru) 2006-12-29
HK1101400A1 (en) 2007-10-18
NZ548367A (en) 2010-06-25
WO2005066131A1 (en) 2005-07-21
IL176740A (en) 2011-09-27
ATE451357T1 (de) 2009-12-15
JP2007519640A (ja) 2007-07-19
US7915295B2 (en) 2011-03-29

Similar Documents

Publication Publication Date Title
AR062109A1 (es) Derivados sustituidos de espirocetal y uso de los mismos como farmacos terapeuticos para la diabetes. composiciones farmaceuticas.
BRPI0908120A8 (pt) Compostos que são inibidores de erk, composição faramacêutica e uso
EA200602060A1 (ru) Производные пирролидин-2-она и пиперидин-2-она, используемые в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы
SV2010003713A (es) Pirimidin-5-carboxamidas sustituidas 281
BRPI0418306A (pt) inibidores da transcriptase reversa não nucleotìdicos
ECSP099571A (es) Derivados pirazólicos como inhibidores de la 11-beta-hsd1
EA201101089A1 (ru) Производные оксадиазола в качестве агонистов рецептора s1p1
WO2008087611A3 (en) Pyrrolidine- and piperidine- bis-amide derivatives
EA201001015A1 (ru) Карбамоиловые соединения в качестве ингибиторов dgat1 190
MA30821B1 (fr) Derives de pyrazoline utiles comme antagonistes des recepteurs de mineralocorticoïdes
ECSP099442A (es) Derivados de heteroaril-pirrolidinil- y -piperidinil-cetona
DE602005016297D1 (de) Antithrombotische diamide
DK1753723T3 (da) Substituerede quinolinderivater som mitotiske kinesininhibitorer
EA200970793A1 (ru) Модуляторы рецепторов, активируемых пролифераторами пероксисом
ATE457302T1 (de) Aromatische etherderivate als thrombin-hemmer
TN2011000429A1 (en) Derivatives of benzothiazines, preparation thereof and application thereof as drugs
UY30356A1 (es) Derivados de 3-halo-n-(2.(4-fluorofenil)-4-oxobutil)-n-metil-5-(trifluorometil)benzamida y composiciones de los mismos.
WO2008078445A1 (ja) 重合性化合物及び重合性組成物
MY151228A (en) Derivatives of 2-oxoalkyl-1-piperazin-2-one, preparation method thereof and therapeutic use of same
TW200745104A (en) Multikinase inhibitor
BRPI0516112A (pt) métodos para neuroproteção
BRPI0510397A (pt) compostos, composições farmacêuticas contendo os mesmos, e métodos de uso dos mesmos
SE0400021D0 (sv) Non-nucleoside reverse transcriptase inhibitors
DK2117552T3 (da) Anvendelse af kondenserede pyrimidinderivater til behandling af autoimmum- og inflammationssygdomme
AR061741A1 (es) Nuevos derivados naftalenicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 18/09/2018, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/12/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 17A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2651 DE 26-10-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.